BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.

doi:10.1007/s11864-022-01006-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.

Current treatment options in oncology - 1 Nov 2022

Zhong Jingqin, Yan Wangjun, Wang Chunmeng, Liu Wanlin, Lin Xinyi, Zou Zijian, Sun Wei, Chen Yong

Abstract excerpt

OPINION STATEMENT: Melanoma is caused by a variety of somatic mutations, and among these mutations, BRAF mutation occurs most frequently and has routinely been evaluated as a critical diagnostic biomarker in clinical practice. The introduction of targeted agents for BRAF-mutant melanoma has significantly improved overall survival in a large proportion of patients. However, there is BRAF inhibitor resistance in...

Topics

Humans
Proto-Oncogene Proteins B-raf
Drug Resistance, Neoplasm
Melanoma
Protein Kinase Inhibitors
Mutation
Biomarkers

Source

Open in PubMed Open full text

Identifiers

PMID: 36181568
DOI: 10.1007/s11864-022-01006-7
PMCID: PMC9596525

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics